GLP-2在非酒精性脂肪性肝病中的研究进展
Research progress of GLP-2 in non-alcoholic fatty liver disease
非酒精性脂肪性肝病(Nonalcoholic Fatty Liver Disease, NAFLD)是一种全球范围内日益普遍的慢性肝脏疾病,已成为成人和儿童最常见的慢性肝脏疾病,其发病率逐年上升,并呈现出低龄化趋势。NAFLD的发生与胰岛素抵抗、肥胖、2型糖尿病等代谢综合征密切相关。近年来,胰高血糖素样肽-2(GLP-2)作为一种在肠道组织中特异表达的激素,其在胰岛素抵抗、脂代谢中的作用也逐渐被发现和重视。本文旨在综述GLP-2在非酒精性脂肪性肝病中的研究进展。
Nonalcoholic Fatty Liver Disease (NAFLD) is an increasingly common chronic liver disease worldwide. It has become the most common chronic liver disease in adults and children. The incidence of NAFLD is increasing year by year and shows a trend of younger age. The occurrence of NAFLD is closely related to insulin resistance, obesity, type 2 diabetes and other metabolic syndromes. In recent years, glucagon-like peptide-2 (GLP-2), as a hormone specifically expressed in intestinal tissues, has been gradually discovered and paid attention to its role in insulin resistance and lipid metabolism. This article aims to review the research progress of GLP-2 in non-alcoholic fatty liver disease.
王馨雨、张淑娟
临床医学内科学基础医学
胰高血糖素样肽-2非酒精性脂肪性肝病肥胖脂代谢胰岛素抵抗
Glucagon-like peptide-2non-alcoholic fatty liver diseaseObesity Lipid metabolismInsulin resistance
王馨雨,张淑娟.GLP-2在非酒精性脂肪性肝病中的研究进展[EB/OL].(2024-12-12)[2025-08-18].https://www.biomedrxiv.org.cn/article/doi/bmr.202502.00018.点此复制
评论